Jay Short

Dr. Jay Short

Jay Short is founder and CEO of the antibody drug company BioAtla, LLC .[1] Previously he was VP of R&D and Operations at Stratagene (now Agilent Technologies), then founder and CEO of Diversa until his departure in 2005.[2] While at Diversa, Dr. Short invented methods of protein and pathway discovery via metagenomics, in addition to key evolution technologies Gene Site Saturation MutagenesisTM (GSSM) and GeneReassemblyTM,[3] and was the first to combine these discovery and evolution technologies.

On December 7, 2015, San Diego-based BioAtla signed a license and option deal with Pfizer, involving BioAtla's Conditionally Active Biologics (CAB) antibody platform and Pfizer's antibody drug conjugate (ADC) payloads.[4] Both companies signed the deal in order to advance development and commercialization of a new class of antibody therapeutics. BioAtla is eligible to receive more than $1.0 billion in up-front, regulatory and sales milestone payments as well as tiered marginal royalties reaching double digits on potential future product sales.[5][6]

Dr. Short is also founder of the E. O. Wilson Biodiversity Foundation , Chairman of the Board of Ciris Energy ,[7] and member of the Board of Directors of Senomyx . Dr. Short received his Ph.D. in Biochemistry from Case Western Reserve University in Cleveland, Ohio and his B.A. with honors in Chemistry from Taylor University in Upland, Indiana.

References

  1. ↑ http://online.liebertpub.com/doi/abs/10.1089/ind.2007.3.013?journalCode=ind&
  2. ↑ Somers, Terri (October 7, 2005). "Diversa CEO resigns from biotech". The San Diego Union-Tribune. Retrieved 12 August 2011.
  3. ↑ http://www.genengnews.com/media/pdf/sequencing_pdf1.pdf
  4. ↑ "BioAtla Enters Into Strategic License And Option Agreement With Pfizer For A New Class Of Antibody Therapeutics". PR Newswire. 7 December 2015. Retrieved 9 December 2015.
  5. ↑ "BioAtla Enters Into Strategic License And Option Agreement With Pfizer For A New Class Of Antibody Therapeutics". PR Newswire. 7 December 2015. Retrieved 9 December 2015.
  6. ↑ "ADCs take CAB ride to tumor-town: $1B deal with Pfizer sets Bioatla on development road". BioWorld. 8 December 2015. Retrieved 9 December 2015.
  7. ↑ http://www.sandiegouniontribune.com/news/2013/feb/24/biotech-whizs-methane-mining-technique-could-be/

External links

This article is issued from Wikipedia - version of the Sunday, February 21, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.